Dual effect of Platelet Factor 4 on the activities of Factor Xa

Biochemical and Biophysical Research Communications
Martine M Fiore, Ian J Mackie

Abstract

Platelet Factor 4 (PF4) prevents inhibition of blood coagulation proteases by heparin via formation of a putative enzyme-PF4 complex. To investigate the contribution of the latter, the activity of factor Xa (fXa) was determined in chromogenic assays measuring hydrolysis of a peptide substrate S2765 or cleavage of the macromolecular substrate prothrombin in the activating complex, prothrombinase. Upon preincubation with fXa and heparin, PF4 at about 250 nM decreased the k(cat) of S2765 hydrolysis about fivefold and that of prothrombin activation about 25-fold. In the presence of saturating fVa, inhibition of fXa by PF4 was abolished, while in the presence of limiting fVa, PF4 altered the interaction of fXa with fVa. Interestingly, high concentrations of PF4 restored fXa activity toward S2765 and prothrombin, indicating a dual effect of PF4 on fXa activities. These findings suggest that PF4 in the presence of heparin is an allosteric effector of the prothrombinase complex.

References

Feb 1, 1980·The Journal of Clinical Investigation·M A Shuman, S P Levine
Feb 1, 1983·The Biochemical Journal·J DentonU Lindahl
Jun 1, 1993·Glycobiology·M Maccarana, U Lindahl
Oct 7, 1997·Biochemistry·S Krishnaswamy, A Betz
Jan 10, 2002·The Journal of Biological Chemistry·Matthias Wilkens, Sriram Krishnaswamy
Jul 30, 2004·Seminars in Thrombosis and Hemostasis·Timothy A Mixon, Gregory J Dehmer
May 18, 2005·The Journal of Biological Chemistry·Michael A BukysMichael Kalafatis
Aug 30, 2007·The Journal of Biological Chemistry·Stéphanie LevigneOlivier D Christophe

❮ Previous
Next ❯

Citations

Jul 6, 2020·Journal of Cardiothoracic and Vascular Anesthesia·Florian FalterMartin Besser

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.